Clinical Trials Logo

Filter by:
NCT ID: NCT02668692 Completed - Psoriasis Vulgaris Clinical Trials

LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis

Start date: February 2016
Phase: Phase 3
Study type: Interventional

To compare the efficacy and safety of LEO 80185 gel with Dovobet® ointment in the treatment of psoriasis in Japanese subjects.

NCT ID: NCT02668653 Completed - Leukemia Clinical Trials

Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)

QuANTUM-First
Start date: September 1, 2016
Phase: Phase 3
Study type: Interventional

Quizartinib is an experimental drug. It is not approved for regular use. It can only be used in medical research. Adults might be able to join this study after bone marrow tests show they have a certain kind of blood cancer (FLT3-ITD AML). Participants will have an equal chance of receiving quizartinib or placebo along with their chemotherapy.

NCT ID: NCT02667665 Completed - Clinical trials for Alzheimer's Disease Dementia

Verification Study and Reactivity Study for the Validity of QuQu Scale

QuQu
Start date: February 19, 2016
Phase: N/A
Study type: Observational

Examine the construct validity, the test-retest reliability, the concurrent validity with the standard dementia rating scales and the reactivity of a novel dementia rating scale "QuQu scale: QUick QUestion scale" final for the evaluation of patients with Alzheimer's Disease Dementia and Mild Cognitive Impairment.

NCT ID: NCT02667587 Completed - Brain Neoplasms Clinical Trials

An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)

CheckMate548
Start date: May 9, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate patients with glioblastoma that is MGMT-methylated (the MGMT gene is altered by a chemical change). Patients will receive temozolomide plus radiation therapy. They will be compared to patients receiving nivolumab in addition to temozolomide plus radiation therapy.

NCT ID: NCT02667483 Completed - Clinical trials for Duchenne Muscular Dystrophy

Study of DS-5141b in Patients With Duchenne Muscular Dystrophy

Start date: October 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I/II study to evaluate the safety, tolerability, efficacy, and pharmacokinetic (PK) profile of DS-5141b in patients with Duchenne muscular dystrophy (DMD) amenable to exon 45 skipping and to determine the dosage for subsequent studies.

NCT ID: NCT02663739 Completed - Aortic Dissection Clinical Trials

Zenith® TXD Post-market Surveillance in Japan

Start date: March 2015
Phase:
Study type: Observational

The study is a post-market surveillance study required by Japanese Regulatory Authorities as a condition of approval

NCT ID: NCT02659696 Completed - Clinical trials for Primary Biliary Cirrhosis

Nalfurafine Hydrochloride for Pruritus in Patients With Primary Biliary Cholangitis

Start date: September 2015
Phase:
Study type: Observational

Nalfurafine hydrochloride is a selective kappa-opioid receptor agonist developed in Japan, and in May 2015 the use of nalfurafine hydrochloride was officially approved in Japan for pruritus in patients with chronic liver diseases including PBC. In the current study, the investigators aimed to assess pruritus and overall QOL before and after administration of nalfurafine hydrochloride in patients with PBC. Furthermore, the investigators took serum sample from the enrolled patients and examine the association of pruritus with possible biomarkers.

NCT ID: NCT02658214 Completed - Clinical trials for Esophageal Squamous Cell Carcinoma

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

Start date: April 28, 2016
Phase: Phase 1
Study type: Interventional

Durvalumab and Tremelimumab in combination with first-line chemotherapy in the following indications: Ovarian/peritoneal/fallopian tube cancer, SCCHN, TNBC, SCLC and gastric/GEJ cancer, PDAC, ESCC.

NCT ID: NCT02658188 Completed - Clinical trials for Restless Legs Syndrome

Long-term Efficacy and Safety of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients

Start date: December 2007
Phase: Phase 3
Study type: Interventional

The objective of this study is to evaluate the efficacy and safety of ASP8825 (gabapentin enacarbil) for long-term treatment of restless legs syndrome patients.

NCT ID: NCT02657434 Completed - Clinical trials for Non-Small Cell Lung Cancer

A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)

Start date: April 30, 2016
Phase: Phase 3
Study type: Interventional

This is a randomized, Phase III, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab in combination with cisplatin or carboplatin + pemetrexed compared with treatment with cisplatin or carboplatin + pemetrexed in participants who are chemotherapy-naive and have Stage IV non-squamous NSCLC. Eligible participants will be randomized by a 1:1 ratio into 2 groups: Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed) and Arm B (Carboplatin or Cisplatin + Pemetrexed). The study will be conducted in two phases: Induction Phase and Maintenance Phase.